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 Chapter 3 
 Cytokine Networks and Cancer Stem Cells 
 Clifford  Liongue ,  Alister  C.  Ward ,  Wei  Duan and  Sarah  Shigdar 
 Abstract  Cell-to-cell communication is an integral function of multicellular 
 organisms. Many of these signals are received by a myriad of cell-surface receptors 
that utilize a range of intracellular signaling pathways to communicate this to the 
nucleus, rapidly impacting on the transcription of target genes in order to elicit the 
desired response, such as proliferation, differentiation, activation, and survival. 
Dysregulation of these important signaling pathways, and networks, often lead to 
pathological conditions due to inappropriate cell responses with negative conse-
quences. The aberrant signaling pathways have been associated with many diseases, 
including cancer. Cytokines and chemokines convey a multitude of messages to the 
target cell, many of which are beneﬁ cial for cancers and cancer stem cells, such as 
proliferation, survival and migration. By hijacking this communication network, 
cancers and cancer stem cells can become invasive and more pathogenic. 
Furthermore, by using these communication systems, cancer stem cells are able to 
evade current therapies. Therefore, novel therapies may be developed to break the 
communication systems of the cancer stem cells. This chapter explores the role of 
the cytokines TGF-β, TNF-α, IL-1 and IL-6 and chemokine CXCL8 as well as 
NF-κB and their role in cancer stem cell survival and maintenance. Emerging thera-
pies are beginning to target the cancer stem cell population, either speciﬁ cally or 
synergistically with existing therapeutic options. These novel therapies may hold 
the key to breaking the communication network of cancer stem cells. 
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1  Introduction 
 During development and throughout life, cells constantly respond to external  stimuli 
and generate an appropriate response, such as proliferation, differentiation, activa-
tion and survival. Among these stimuli are cytokines and chemokines, which play 
an essential role in the development and regulation of a range of cell types, in par-
ticular those of the immune and hematopoietic systems.  Cytokine signaling plays a 
major role in the initiation, propagation and resolution of inﬂ ammation. Given that 
cancer is now recognized as a disease of inﬂ ammation, it is no surprise that cyto-
kines contribute strongly to the development and propagation of cancer and cancer 
stem cells. This Chapter aims to explore the contribution of cytokines to the pheno-
type of cancer stem cell phenotype, as well as identifying possible therapeutic tar-
gets and postulating on the effects that personalized medicine may have on the 
future treatment of cancer patients. 
2  Tumor Microenvironment,  Inﬂ ammation ,  EMT 
and  Cancer Stem Cells 
 Inﬂ ammation is a natural response to injury (Coussens and Werb  2002 ). The pres-
ence of a tumor triggers an inﬂ ammatory response, creating a microenvironment that 
may enhance the dissemination of cancer cells (Hanahan and Weinberg  2000 ,  2011 ). 
Key features of the tumor microenvironment include endothelial cells, bone marrow 
derived stromal cells and inﬁ ltrating white blood cells, which migrate into the tumor 
following cytokine and chemokine recruitment via the tumor cells or surrounding 
stroma (Grivennikov et al.  2010 ; Hanahan and Weinberg  2011 ). Within the tumor 
mass are so-called cancer stem cells ( CSCs ), which are a small subset of cells with 
the ability to proliferate and form new tumors (Al-Hajj et al.  2003 ; Koch et al.  2010 ). 
The key functional properties of these cells are self-renewal, multi-potent differentia-
tion and the capacity to generate a heterogeneous lineage of all types of cancer cells 
comprising a tumor (Shackleton  2010 ; Clevers  2011 ). These CSCs also have the 
potential to lose their epithelial phenotype, becoming motile and invasive, and taking 
on a mesenchymal phenotype, a process known as the epithelial-to-mesenchymal 
transformation ( EMT ), and representing an important step in metastasis (Singh and 
Settleman  2010 ; Biddle and Mackenzie  2012 ; Brabletz  2012 ). 
 A number of cytokines and chemokines have been shown to be released during 
inﬂ ammation that play a vital role in the progression of cancer, affecting key  CSC 
phenotypes such as  EMT . These include  Interleukin (IL)-1, IL-6, IL-8 (CXCL8), 
tumor necrosis factor-alpha ( TNF-α ), transforming growth factor-beta ( TGF-β ) and 
 NF-κB . Communication between cells is not unidirectional, with both immune and 
tumors cells producing cytokines and chemokines (Lu et al.  2006 ). Such cues, as 
along with additional environmental factors, induce the changes that enable cancer 
cells to metastasize (Hanahan and Weinberg  2011 ). 
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 Tumor associated macrophage s ( TAMs ) play a major role in the progression of 
cancer. The secretion of IL-1 and  TNF-α by TAMs has been shown to support the 
steps involved in invasion and metastasis (Biswas et al.  2013 ). Secretion of TNF-α 
by TAMs and other immune cells can also up-regulate the secretion of  TGF-β by 
cancer associated ﬁ broblasts ( CAFs ) and immune cells, which is an inducer of IL-1, 
IL-6 and IL-8 (Mani et al.  2008 ). IL-6 is also secreted by CAFs, TAMs, other 
immune cells, as well as by the cancer cells themselves, forming a positive feedback 
loop (Shigdar et al.  2014 ). The cancer cells also secrete IL-8, MCP-1 and RANTES, 
which promote proliferation of stromal cells, including endothelial cells (Levina 
et al.  2008 ), with RANTES and MCP-1 also able to attract tumor-inﬁ ltrating lym-
phocytes (Ji and Zhang  2010 ). Both IL-6 and IL-8 have been shown to mediate 
chronic inﬂ ammation, suggesting that cancer cells are directly involved in stimulat-
ing the inﬂ ammatory process (Korkaya et al.  2011 ,  2012 ). 
 How then do these cytokines and the inﬂ ammatory process contribute towards a 
 CSC phenotype? This ultimately relates to the downstream signaling pathways 
induced, which act on key genes to modify the phenotype of  CSCs . However, this is 
a multi-step process. Using the analogy of the ‘never-healing wound’, proliferating 
tumor cells and the surrounding activated stroma secrete cytokines and chemokines 
to attract immune cells which secrete further factors to induce activation and/or 
inﬁ ltration of other cells. The center of this ‘ball of cells’ becomes hypoxic, leading 
to the up-regulation of  Hypoxia -inducible factor-1 alpha (HIF-1α), which acts in 
concert with cytokine-induced Snail, Twist1 and Stat3 to induce epithelial- 
mesenchymal transition ( EMT ). This then leads to the dissemination of CSCs to 
distant metastatic sites, where these cells then initiate secondary tumors (Mani et al. 
 2008 ), but also leaving behind a population of CSC-like cells (Singh and Settleman 
 2010 ; Kong et al.  2011 ). Indeed, it is thought that the de-differentiation of cancer 
cells into CSCs, is the ﬁ rst step in the process towards EMT (Fig.  3.1 ). Moreover, 
the aberrant activation of EMT enhances cancer cell motility and dissemination but 
also confers a stem-cell like phenotype, as evidenced by gene expression patterns, 
and leads to an increase in the CSC population (Chaffer et al.  2011 ; Hanahan and 
Weinberg  2011 ; Brabletz  2012 ), pointing to the close association between CSCs 
and EMT. However, cytokines are also important in maintaining CSCs and inducing 
other phenotypes in these cells in addition to EMT.
3  Transforming Growth Factor-Beta 
 Transforming growth factor-beta ( TGF-β ) is secreted by immune cells during 
 normal wound healing in order to trigger surrounding epithelial cells to undergo 
 EMT enabling them to migrate to the site of the wound for repair (Biddle and 
Mackenzie  2012 ) (Fig.  3.2 ). However, this process becomes perturbed during can-
cer development. Immune cells migrate to the area of a tumor in an attempt to heal 
the ‘wound’ and secrete cytokines, such as TGF-β. The cancer cells, meanwhile, 
have developed oncogenic mutations that render them more responsive to these 
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EMT-inducing signals (Biddle and Mackenzie  2012 ), while also converting TGF- 
β’s normal growth inhibitory role into a growth promoting role (Padua and Massague 
 2009 ; Asiedu et al.  2011 ). To understand how TGF-β induces EMT, and thus  CSCs , 
an understanding of the signaling pathways involved is required to induce EMT, 
TGF-β signals via both a Smad-dependent and Smad-independent transcriptional 
pathway (Fig.  3.3 ). The Smad-dependent pathway involves phosphorylation of 
 Fig. 3.1  Factors promoting cancer stem cell formation . Schematic representation of the link 
between tumor microenvironment, inﬂ ammation, and oncogenic signaling in cancer stem cell for-
mation. The  CSCs develop a number of phenotypes, including migratory capacity via an epithelial- 
mesenchymal transition enabling the dissemination of the tumor (Adapted from (Mani et al.  2008 ; 
Singh and Settleman  2010 ; Kong et al.  2011 ; Shigdar et al.  2014 )) 
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Smad2 and Smad3, which then form heteromeric complexes with Smad4. These 
complexes then translocate into the nucleus where they control transcription of 
EMT target genes (Massague  2000 ; Derynck and Zhang  2003 ). The Smad- 
independent pathway activates  Ras /Erk, c-Jun N-terminal kinase (JNK), phospha-
tidlylinsitol- 3 (PI3) kinase, Par6, and Cdc42 GTPases, which have also been 
associated with TGF-β-induced EMT (Derynck and Zhang  2003 ).
 Autocrine  TGF-β signaling has been linked to  EMT and migration, as well as 
maintenance of a stem cell-like population. Indeed, TGF-β secreted by cancer cells 
can mediate the differentiation of ﬁ broblasts into myoﬁ broblasts, or  CAFs , which 
then secrete more TGF-β into the microenvironment, thus further promoting EMT 
(Fig.  3.2 ). In a recent study, the abrogation of TGF-β autocrine signaling resulted in 
decreased expression of vimentin and Snail, and enhanced expression of  E-cadherin , 
indicating a reduction in EMT potential. In addition, the cancer stem cell-like mark-
ers Integrin β1, Notch 1 and aldehyde dehydrogenase 1/2 were also reduced. Finally, 
expression of Gli1, a component of the hedgehog signaling pathway involved in 
stem cell self-renewal was reduced, indicating the importance of this pathway for 
both EMT and  CSCs (Liu et al.  2012 ). 
 Another consequence of  TGF-β signaling is the decreased expression of the 
p15 INK4b and p21 CIP21 tumor suppressor genes, which act by stabilizing cyclin- 
dependent kinase inhibitors. It is thought that as the balance shifts between 
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 Fig. 3.2  Role of  TGF-β in  CSC phenotypes. Mode of action of paracrine and autocrine TGF-β 
signaling involved in cancer stem cell phenotypes, including epithelial-mesenchymal transition 
(Adapted from (Biddle and Mackenzie  2012 )) 
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 SMAD- dependent and SMAD-independent signaling, the cyclin-dependent kinase 
inhibitors fail to be induced, thus allowing cell proliferation to continue unchecked. 
However, at low levels of c-Myc, TGF-β typically induces the expression of p21, a 
cell cycle inhibitor, which in cancer cells, could contribute towards the  CSC quies-
cent state (Kubiczkova et al.  2012 ). As well, Notch is activated in the immediate 
vicinity of active tumor progenitors, and Notch has been linked to p21 activation, 
thus suggesting that Notch, via p21, drives a quiescent phenotype consistent with 
 CSCs , via some feedback control mechanism (Medema  2013 ). Once p21 is acti-
vated, several other signaling cascades are blocked, including c-Myc (Abbas and 
Dutta  2009 ) thus perpetuating the CSC phenotype. However, other pathways are 
activated which reduce these effects in some of the CSCs, thus leading to the acqui-
sition of an  EMT phenotype (Fig.  3.2 ). 
 While  TGF-β can induce  CSC phenotypes such as  EMT , this effect has been 
shown to be transitory and required tumor necrosis factor (TNF)-α for more stable 
phenotypic changes (Mani et al.  2008 ; Asiedu et al.  2011 ). Moreover,  TNF-α can 
up-regulate TGF-β expression at the transcriptional level and accelerate TGF-β 
induced EMT dramatically (Bates and Mercurio  2003 ). 
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 Fig. 3.3  Signaling pathway s inﬂ uencing  CSC phenotypes. Simpliﬁ ed schematic of the signaling 
pathways downstream of  TNF-α and  TGF-β involved in key cancer stem cell phenotypes (Adapted 
from (Sethi et al.  2008 ; Balkwill  2009 ; Storci et al.  2010 ; Lee et al.  2012 ; Li et al.  2012a ; Katsuno 
et al.  2013 ) 
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4  Tumor Necrosis Factor-Alpha 
 Tumor necrosis factor (TNF) was ﬁ rst identiﬁ ed as a soluble factor released by host 
cells in response to a bacterial endotoxin that caused necrosis of tumors in both 
humans and animal models (Balkwill  2009 ). Amongst the large TNF superfamily, 
 TNF-α has been recognized as a particularly important member (Balkwill  2009 ). 
TNF-α has a well-established pro-inﬂ ammatory function, shown to be an important 
mediator of the chronic inﬂ ammation of the bowel observed in irritable bowel dis-
ease (IBD). Indeed, TNF antagonists have been used quite successfully for the treat-
ment of IBD, Chrohn’s disease and ulcerative colitis (Balkwill  2009 ; Ben Musa 
et al.  2014 ), as well as rheumatoid arthritis, psoriasis, severe chronic asthma, anky-
losing spondylitis and sarcoidosis (Balkwill  2009 ). Moreover, given its pro- 
inﬂ ammatory role, TNF-α has also been shown to act as a tumor initiator by 
stimulating the production of molecules that lead to DNA damage and mutations 
such as reactive oxygen and nitrogen species (RONS), and as a tumor promoter by 
altering cell proliferation and death (Hartnett and Egan  2012 ). TNF-α mediates its 
effects through binding to two different receptors with subsequent intracellular sig-
naling occurring through several different pathways (Sethi et al.  2008 ; Egea et al. 
 2011 ). It contributes to malignant transformation through the up-regulation of  c-Fos 
and  c-Myc via  NF-κB (Wang et al.  2013 ) (Fig.  3.3 ). 
 The role of  TNF-α , however, is far from simple since it has also been shown to be 
cytotoxic and possess anti-tumor effects in several malignant diseases (Soria et al. 
 2011 ). The latter are thought to be related to its effects in destroying the tumor vas-
culature (Balkwill  2009 ), and may represent an effective  therapeutic strategy early in 
cancer development (Ben Musa et al.  2014 ). However, it is now known that in 
advanced stages of cancer, the destruction of the tumor vasculature can lead to 
enhanced metastasis through  EMT (Simon and Keith  2008 ; Mayol et al.  2009 ). 
Interestingly, it appears that low levels of TNF-α act as a tumor promoter and a recent 
study has shed light on how these low levels are maintained. The microRNA (miRNA) 
miR-130a, which has been demonstrated to promote cell survival in several cell lines, 
was shown to directly target the 3’UTR region of TNF-α, repressing its translation. 
Additionally, TNF-α stimulated enhanced miR-130a levels via  NF-κB , providing a 
negative feedback loop that maintains TNF-α at levels that can promote tumor 
growth, at least in cervical cancer cells (Zhang et al.  2014 ). However, as shown quite 
eloquently in a previous study, ovarian cancer patients with the highest levels of 
TNF-α experienced the most intense down-regulation following monoclonal anti-
body therapy against TNF-α, although in mouse studies, a similar blockade of TNF-α 
resulted in decreased vasculature (Kulbe et al.  2012 ). Additionally, given that TNF-α 
therapy has been associated with an increased risk of malignancies, care must be 
taken when considering this as a therapeutic option (Bongartz et al.  2006 ). 
 This data suggests another potential link between  TNF-α ,  EMT and  CSCs . If 
blockade of TNF-α leads to a decreased vasculature, does this lead to a level of 
hypoxia required to promote  CSC formation, and if so is this how miR-130a con-
tributes to tumor promotion? In support of this, hypoxia is known to increase the 
number of  CD133 + CSC within a tumor mass, through the activation of Oct4 and 
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 Notch signaling (Simon and Keith  2008 ; Mayol et al.  2009 ). Additionally, tumor 
hypoxia increases  TGF-β secretion from cancer cells, thus triggering EMT (Jing 
et al.  2011 ). TNF-α can also cause the production of reactive oxygen species ( ROS ) 
from mitochondria under hypoxic conditions, and both ROS and  NF-κB can facili-
tate EMT in certain cell types (Jing et al.  2011 ). As well, increased intracellular 
ROS levels may induce DNA damage within CSCs, resulting in additional muta-
tions that promote disease progression (Tanno and Matsui  2011 ). Moreover, as 
described previously, the induction of Notch signaling leads to the activation of p21, 
resulting in quiescence (Medema  2013 ). Indeed, it is this link between TNF-α and 
Notch, whose activation occurs following prolonged exposure to TNF-α, that con-
tributes to the CSC phenotype (Lee et al.  2012 ). 
5  Interleukin -1 
 The  Interleukin -1 (IL-1) cytokine family represent key mediators of inﬂ ammation 
and innate immune response, consisting of 11 cytokines and 10 receptors. Cells of 
the innate immune system, such as monocytes and macrophages are major sources 
of the two IL-1 cytokines, IL-1α and IL-1β, which both signal through the same 
receptor complex consisting of IL-1 receptor 1 (IL-1R1) and IL-1 receptor acces-
sory protein (IL-1Rap). There are two mechanisms for controlling IL-1 signaling, 
either via the by competitive binding of the IL-1 Receptor antagonist (IL-1Ra) to 
the IL-1 receptor complex, or recruitment of a decoy receptor IL-1R2 that is unable 
to induce signal transduction (Dinarello  2011 ).  Signaling pathway s activated by 
IL-1 cytokines include myeloid differentiation primary response gene 88 (MYD88) 
and interleukin-1 receptor activated protein kinase (IRAK) as well as the  NF-κB 
and PI3K pathways (Weber et al.  2010 ). The IL-1 family cytokines exist as an “inac-
tive” uncleaved IL-1 which is cleaved to produce an “active” form that is able to 
signal via its cognate receptor complex (Werman et al.  2004 ). 
 Although cancer cells express IL-1α, its role varies depending on its state of 
cleavage. If IL-1α is uncleaved, it can act as a tumor suppressor, possibly via its 
ability to form a non-signaling complex with IL-1R1 that may act as an antigen for 
the immune system. Indeed, uncleaved IL-1α has been shown, at least initially, to 
reduce tumor load. Conversely, if IL-1α is cleaved it becomes a potent pro- 
inﬂ ammatory cytokine that favors tumor progression by promoting invasiveness 
and metastasis (Rider et al.  2013 ). Clearly, dual-function cytokines are unique as 
they do not require their cognate receptors to be expressed for autocrine signaling, 
and are able to elicit a function without their canonical signaling cascade. Therefore, 
dual function cytokines such as IL-1α require careful further study to delineate their 
exact roles in cancer. 
 Unlike IL-1α, IL-1β is not a dual function cytokine and requires cleavage of the 
“inactive” form before it becomes functional (Werman et al.  2004 ). IL-1β has been 
implicated in several types of cancer, including glioma, acute myeloid leukemia and 
colon cancer (Turzanski et al.  2004 ; Li et al.  2012b ; Wang et al.  2012 ). The glioma 
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cell line, LN-229 lacks a  CSC phenotype, but following addition of IL-1β and 
TGF- β increased its “stemness” changing it to a more CSC phenotype. This is of 
clinical relevance, since increased levels of both IL-1β and TGF-β occur in high 
grade gliomas with poor clinical outcomes for patients (Wang et al.  2012 ). Similarly, 
IL-1β can induces colon CSC self-renewal and increase invasiveness in cooperation 
with zinc ﬁ nger E-box binding homeobox 1 (Zeb1) (Li et al.  2012b ). IL-1β can also 
act as via antiapoptosis pathways to maintain the blast cells in acute myeloid leuke-
mia (AML) (Turzanski et al.  2004 ). In addition, IL-1Rap is overexpressed in chronic 
myeloid leukemia stem cells with an IL-1Rap antibody able to induce antibody- 
dependent, cell-mediated cytotoxicity to these cells, but not those expressing low 
levels of IL-1Rap such as normal bone marrow cells (Askmyr et al.  2013 ). 
6  Interleukin -6 
 The  Interleukin -6 receptor (IL-6R) family consists of receptors composed of 
receptor chains related to the ligand-speciﬁ c IL-6Rα or the archetypical GP130 
(Boulay et al.  2003 ). The founding member, IL-6, is a pleiotropic cytokine that 
utilizes a receptor complex consisting of the ligand speciﬁ c IL-6Rα and shared 
GP130 receptor subunits which signals via the downstream JAK2 and STAT3. 
One of the many roles of IL-6 is the maintenance of stem cells (Ernst et al.  1996 ; 
Notara et al.  2010 ). Therefore tight regulation of IL-6 expression and, in particu-
lar, its receptor IL-6Rα is required for normal development and homeostasis. The 
disruption of normal IL-6Rα expression is often pathogenic, and has been reported 
to have a role in several cancers, such as breast, ovarian and prostate cancers 
(Knupfer and Preiss  2007 ). 
 Serum IL-6 levels have been identiﬁ ed to correlate with poor prognosis for breast 
cancer patients (Sansone et al.  2007 ). One key role for IL-6 in breast cancer is to 
maintain the cancer stem cell population, with disruption of  IL-6 promoter methyla-
tion able to increase IL-6 levels and thereby increasing cancer stem cell mainte-
nance (D’Anello et al.  2010 ). Furthermore, IL-6 is also able to induce  EMT in 
breast cancer cells further enhancing their  CSC properties (D’Anello et al.  2010 ). 
 Breast cancer s are a heterogeneous population of cells consisting of breast CSC and 
also differentiated breast cancer cells with the proportion of breast CSC and breast 
cancer cells varying depending on the microenvironmental conditions. The propor-
tion of breast CSC to breast cancer cells is maintained by IL-6, a function that has 
also been observed in a prostate cancer cell line (Iliopoulos et al.  2011 ). Trastuzumab 
is a monoclonal antibody inhibitor for the v-erb-b2 avian erythroblastic leukemia 
viral oncogene homolog 2 (ERBB2) protein (also known as human  EGF receptor 2, 
 HER2 ), with overexpression of ERBB2 associated with aggressively proliferative 
breast cancer (Schroeder et al.  2014 ). Moreover, treatment of breast cancer with 
trastuzumab often leads to an enrichment of the breast CSC population with 
increased IL-6 expression. Antibody blockade of IL-6Rα is able to reduce the 
enrichment of the breast CSC population, leading to decreased tumor growth 
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(Korkaya et al.  2012 ). Therefore, combination treatment with a compound targeting 
non-stem cancer cells as well as a CSC targeting drug, such as Metformin, may be 
useful in avoiding CSC enrichment, with implications for the ability to successfully 
ablate the cancer (Hirsch et al.  2009 ; Iliopoulos et al.  2011 ). 
7  Interleukin -8 
 Chemokine (C-X-C motif) ligand 8 or interleukin-8 (IL-8) is a proinﬂ ammatory 
chemokine and signals via two cell surface receptors, preferentially CXCR1 but 
also CXCR2 (Gales et al.  2013 ). These cell surface 7 transmembrane domain 
receptors are coupled with α, β and γ G proteins that induce intracellular signaling 
pathways that mediate cell survival, proliferation, angiogenesis and cell migration 
(Kobilka  2007 ), which include PI3K, RAS, JAK/STAT and WNT (Waugh and 
Wilson  2008 ). The CXCL8/CXCR1/CXCR2 signaling axis has been implicated in 
several cancers including melanoma (Singh et al.  2010 ), kidney (Liang-kuan et al. 
 2014 ), breast (Schillace et al.  2014 ) and pancreatic cancer (Chen et al.  2014 ). 
 CXCL8 is expressed by a wide variety of cells, particularly those of the immune 
system, and atypically by several cancers. Paracrine or autocrine signaling is 
achieved via CXCR1 (Chen et al.  2014 ) and CXCR2 (Liu et al.  2011 ) expressed in 
breast cancer cells, including  CSCs . Indeed, increased CXCL8 serum levels have 
been shown to increase breast  CSC activity, as judged by mammosphere formation 
(Singh et al.  2013 ). Similarly, CXCL8 and CXCR1 have been associated with pan-
creatic CSCs, with expression of CXCR1 correlating with that of pancreatic CSC 
markers, which has been linked with a lower survival rate due to metastasis of pan-
creatic cancer cells (Chen et al.  2014 ). The importance of CXCL8 signaling via 
CXCR1 has been demonstrated by inhibition of CXCR1, either by repertaxin, a 
small molecule inhibitor, or by a CXCR1 blocking antibody, which resulted in 
apoptosis of breast CSC and overall reduction of cancer load (Ginestier et al.  2010 ). 
Combined inhibition of CXCL8 and ERBB2, the latter of which is dysregulated in 
25 % of breast cancers (Slamon et al.  1987 ), improves treatment in a synergistic 
manner (Singh et al.  2013 ). 
8  The Central Role of  NF-κB Pathway 
 The  NF-κB pathway provides one of the major links between inﬂ ammation,  CSCs 
and  EMT . Several different stimuli can activate it. These factors include HIF-1α, 
which is induced in normoxic and cancer cells following stimulation by pro- 
inﬂ ammatory cytokines, such as  TNF-α , IL-1β or IL-6 (Lu et al.  2006 ; Korkaya 
et al.  2012 ). Activation of the NF-κB cascade usually results in nuclear translocation 
and activation of p65 (Fig.  3.3 ). The p65 protein is a multifunctional transcription 
factor that elicits its physiologic function by regulating target gene expression upon 
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NF-κB activation. TNF-α, either from macrophages or the tumor microenvironment 
up-regulates the canonical NF-κB signaling through activation of IKKβ. Once up-
regulated, activation of p65 follows and this protein then translocates to the nucleus 
where it induces Twist 1 expression thus promoting tumor metastasis via the 
EMT. This p65-induced EMT is accompanied by an increase in stem cell- like prop-
erties (Li et al.  2012a ). Following the activation of the NF-κB pathway, several 
downstream events occur, such as the suppression of apoptosis. As well, the EMT 
regulators, Snail and Slug, are activated, thus promoting EMT (Korkaya et al.  2012 ) 
(Fig.  3.4 ).
 It is interesting to note that  NF-κB activation can stimulate different factors, 
depending on the cell of origin in the tumor. In basal-like breast cancer, NF-κB 
induces the expression of JAG1, leading to the Notch-dependent expansion of  CSCs 
in a non-cell-autonomous manner (Yamamoto et al.  2013 ). However, it has also 
been shown that epigenetic mechanisms are regulated by NF-κB, with IKK-β regu-
lating Lin28B, a RNA binding protein, which sustains the stemness of breast CSCs. 
This activation of Lin28B decreases Let-7 expression, leading to higher levels of 
IL-6, thus activating Stat3, and further stimulating NF-κB (Iliopoulos et al.  2011 ). 
 During inﬂ ammation  NF-κB is able to promote the production of  ROS , thus dam-
aging DNA in surrounding epithelial cells, though in cancer this effect could cause 
the relevant mutations required for cancer cell continuation. Once NF-κB is activated 
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 Fig. 3.4  The diverse roles of  NF-κB (Adapted from (Baud and Karin  2009 ; Prasad et al.  2010 ; Li 
et al.  2012a )).  A20 zinc ﬁ nger protein A20 (also known as TNFAIP3),  Bcl-2  B-cell lymphoma 
protein 2,  Bcl-XL also known as Bcl-2 like 1,  BFL1 also known as Bcl2A1,  CDK2 cyclin-depen-
dent kinase 2,  c-IAP-2 cellular inhibitor of apoptosis 2,  COX2 cyclooxygenase 2,  ELAM1 endothe-
lial adhesion molecule 1,  FLIP also known as casp8,  HIF-1α hypoxia-inducible factor-1α,  ICAM1 
intracellular adhesion molecule 1,  IEX-1 L radiation-inducible immediate early gene (also known 
as IER3),  IL interleukin,  iNOS inducible nitric oxide synthase,  MCP2 monocyte chemoattractant 
protein 1 (also known as CCL2),  MIP2 macrophage inﬂ ammatory protein 2,  MMP9 matrix metal-
loproteinase 9,  MnSOD manganese superoxide dismutase,  TNF tumor necrosis factor,  TRAF1/2 
TNF receptor-associated factor,  uPA urokinase plasminogen activator,  VEGF vascular endothelial 
growth factor,  XIAP X-linked inhibitor of apoptosis protein 
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in gastric epithelial cells, it stimulates the transcription of IL-1, IL-6, IL-8,  TNF-α 
and cyclooxygenase-2 (COX-2), which can further propagate the NF-κB activation 
response. How does this then lead to cancer progression, as this response to inﬂ am-
mation would be wound-healing, rather than promoting immortality? One sugges-
tion is that some of its immune and inﬂ ammation-related target genes are not activated 
(Karin et al.  2002 ). It is also possible that mutations arise in the genes encoding the 
NF-κB/IκB family members that allows oncogenes to activate NF-κB (Karin et al. 
 2002 ; Karin  2009 ). One recent study investigated the regulation of the NF-κB path-
way by miRNAs. This study found that in epithelial ovarian cells, Twist1 negatively 
regulated NF-κB dependent cytokine production (Yin et al.  2010 ). This seems coun-
terintuitive as NF-κB increases Twist1 expression. However, this process is mediated 
by the microRNA, miR-199a which is frequently down- regulated during cancer pro-
gression (Fornari et al.  2010 ; Yin et al.  2010 ). Yin and colleagues went on to show, 
through knock-down experiments, that while Twist could inﬂ uence IKKβ levels, 
TNF-α was required to induce RANTES production (Yin et al.  2010 ). 
9  Therapeutic Prospects 
 While multiple factors are known to contribute to cancer formation and the cancer 
stem cell phenotype, cytokines are becoming recognized as one of the most viable 
targets for cancer therapeutics (Table  3.1 ). Given the positive feedback loops that 
drive  CSC renewal, agents that can inhibit inﬂ ammatory cytokines or block inﬂ am-
matory signaling pathways could potentially target and eradicate the CSC popula-
tion. While there have been a number of disappointments, there have been a few 
successes.
 There has been promising pre-clinical data from  TGF-β -based therapeutics, the 
majority of these therapeutics caused harmful off-target effects which have pre-
vented further clinical development (Perrot et al.  2013 ). TGF-β signaling begins 
when a ligand binds, and a type II receptor (TβRII) recruits and phosphorylates a 
type I receptor (TβRI). This TβRI is also known as an activin receptor-like kinase 
(ALK) and there are seven known type I ALK receptors, though ALK5 is the most 
speciﬁ c for TGF-β (Mori et al.  2004 ).  Targeting of the downstream ALK5 induced 
a range of toxicities, such as heart valve, hemorrhagic, degenerative and  inﬂ ammatory 
lesions due to incomplete speciﬁ city. Galunisertib (LY2157299), developed by Eli 
Lilly, demonstrates cardiovascular toxicities (Gueorguieva et al.  2014 ), but has been 
used in several studies investigating whether it can sensitize  CSCs to chemotherapy 
(Connolly et al.  2012 ; Perrot et al.  2013 ). It is also possible that this drug can be 
added to current therapeutic strategies to augment and enhance treatment regimens 
(Bhola et al.  2013 ) (Table  3.2 ).
 Other options for targeting  TGF-β include antisense oligonucleotides and 
 monoclonal antibodies. Trabedersen (AP12009) is an antisense oligonucleotide that 
targets TGF-β2 mRNA (Schlingensiepen et al.  2011 ) which showed promise in 
phase I and phase II trials (Joseph et al.  2013 ). Efforts are being made to develop it 
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as a drug for systemic delivery rather than the prior intra-cranial infusion 
(NCT00761280). Fresolimumab (GC1008) is a human anti-TGF-β monoclonal 
antibody that has been investigated for the treatment of advanced malignant mela-
noma and renal cell carcinoma. In initial phase I trials, no dose-limiting toxicities 
were observed and preliminary evidence of anti-tumor activity was seen in 25 % of 
patients (Morris et al.  2014 ). Further studies are now being initiated for the treat-
ment of metastatic breast cancer (NCT01401062). 
 TNF-α inhibition has fallen far short of expectations due to its high systemic 
toxicity (Burton and Libutti  2009 ). Clearly, care must be taken, as seen with the 
initial trials of TNF-α administration where systemic delivery was associated with 
severe toxicity and no, or limited, therapeutic effect (Mukaida et al.  2011 ). However, 
recent studies using an anti-TNF-α monoclonal antibody, inﬂ iximab, have shown 
disease stabilization in patients with advanced cancers (Harrison et al.  2007 ; Brown 
et al.  2008 ). Etanercept, a soluble TNFR2 fusion protein that binds and neutralizes 
TNF-α, was also found to stabilize disease in a minority of ovarian cancer patients 
(Balkwill  2009 ). There are currently ongoing clinical trials on both of these agents. 
 Due to the roles that interleukins play in other health and disease states, includ-
ing inﬂ ammation, caution has also been exercised in the use of agents targeting 
IL-1, IL-6 and IL-8 in cancer. However, because of their role in other diseases, a 
wealth of information has been garnered from previous clinical trials. IL-1β has 
proven a successful therapeutic target in septic shock and rheumatoid arthritis, with 
the recombinant IL-1 receptor antagonist, Anakinra, having a remarkable safety 
record (Dinarello  2010 ).  Clinical trial s have been conducted with Anakinra in a 
 Table 3.1  Selection of therapeutic strategies for targeting cytokine networks 
 Name  Target  Type 
 Clinical 
trials  References 
 Galunisertib  Transforming growth 
factor receptor 
 Small molecule 
drug 
 III  Gueorguieva et al. 
( 2014 ) 
 Trabedersen  Transforming growth 
factor-beta 2 
 Antisense 
oligonucleotide 
 III  Joseph et al. ( 2013 ) 
 Fresolimumab  Transforming growth 
factor-beta 
 Monoclonal 
antibody 
 II  Morris et al. ( 2014 ) 
 Inﬂ iximab  Tumor necrosis 
factor-alpha 
 Monoclonal 
antibody 
 III  Harrison et al. ( 2007 ), 
Brown et al. ( 2008 ) 
 Etanercept  Tumor necrosis 
factor-alpha 
 Neutralizing 
protein 
 III  Balkwill ( 2009 ) 
 N/A  Interleukin- 1 receptor 
accessory protein 
 Monoclonal 
antibody 
 N/A  Askmyr et al. ( 2013 ) 
 Siltuximab  Interleukin- 6  Monoclonal 
antibody 
 III  Jones et al. ( 2011 ) 
 Repertaxin  CXCR1  Small molecule 
drug 
 II  Ginestier et al. ( 2010 ) 
 Curcumin  NF-κB  Natural product  I  Gupta et al. ( 2013 ) 
 DTP3  NF-κB (GADD45β/
MKK7) 
 Small molecule 
drug 
 Late 2015  Tornatore et al. ( 2014 ) 
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number of malignant disorders. One trial combined Anakinra with Dexamethasone 
to treat patients with smoldering or indolent multiple myeloma (NCT00635154), 1 
patient achieved a complete response with Anakinra alone (n = 54), and when com-
bined with desamethasone, 14 patients achieved a response to treatment (n = 29). 
Additionally, 49 patients out of the 54 were still alive and progression-free at 6 
months, with a median duration of response recorded as 41.9 months, indicating 
some effectiveness. There are currently ﬁ ve other clinical trials currently recruiting 
to assess the efﬁ cacy of Anakinra in combination with other chemotherapeutic 
agents. However, as IL-1 plays a role in angiogenesis, care must be taken to develop 
appropriate clinical endpoints. 
 IL-6 targeting therapeutics have also been trialed in a number of malignant dis-
orders, and have typically utilised monoclonal antibodies. CNTO 328 is a human-
ized monoclonal antibody (Guo et al.  2012 ). However, results have been limited. 
One study in patients with non-hormone responsive metastatic prostate cancer 
(NCT00433446) was not completed due to signiﬁ cant disease progression. Another 
clinical trial assessing the efﬁ cacy of CNTO 328 in myelodysplastic patients was 
terminated due to a lack of sufﬁ cient efﬁ cacy (NCT01513317). There is currently 
only one trial active, which will assess the efﬁ cacy of CNTO 328 in patients with 
high-risk smoldering multiple myeloma (NCT01484275). However, some efﬁ cacy 
has been observed in patients with renal cell carcinoma and ovarian cancer (Guo 
et al.  2012 ), suggesting it may be an effective therapeutic in some cancers, either as 
single or in combination therapy. 
 The use of IL-8 targeted therapies has been investigated in inﬂ ammatory diseases 
but to date, there is limited information on the efﬁ cacy in cancer. In vitro and in vivo 
studies have demonstrated inhibitory effects on tumor growth, angiogenesis and 
tumor dissemination, but these results have not be exploited in clinical trials (Skov 
et al.  2008 ). There is currently one pilot study investigating the safety proﬁ le in 
early breast cancer patients (NCT01861054) and an ongoing study to evaluate 
reparixin with weekly paclitaxel in patients with  HER2 -negative metastatic breast 
cancer (NCT02001974). Again, while safety has not proven to be an issue to date, 
only time will tell whether this  therapeutic strategy is efﬁ cacious. 
 The  NF-κB pathway is an intriguing transcription factor to target. This is because 
non-steroidal anti-inﬂ ammatory drugs, such as aspirin and salicylates, have been 
shown to be effective at inhibiting NF-κB activation (Karin et al.  2004 ). Indeed, 
cancer rates in aspirin users has been shown to be far reduced compared to the nor-
mal population (Cuzick et al.  2009 ). The most commonly accepted mechanism by 
which this is thought to occur is via inhibition of COX and thus prostaglandin pro-
duction, although a prostaglandin inhibitor, indomethacin, failed to elicit an effect 
on NF-κB. Aspirin and salicylates do, however, inhibit some NF-κBs target genes 
(Karin et al.  2004 ). One of the issues with targeting the NF-κB is its role in inﬂ am-
mation, and thus any therapeutic should be transient so as not to cause immunosup-
pression (Baud and Karin  2009 ). Additionally, care must be taken so as to not 
enhance the production of IL-1β and related cytokines during bacterial infections, 
which has been a surprising side-effect of NF-κB inhibition (Greten et al.  2007 ; 
Baud and Karin  2009 ). While there are problems with targeting this pathway, there 
are a few drugs that have entered or are about to enter clinical trials. 
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 Curcumin , derived from turmeric, is a natural product that has been shown to 
block IKK activation (Hussain et al.  2008 ). It has been well tolerated and there have 
been no associated toxicities. While there have been concern over the absorption of 
curcumin, bioavailability has been demonstrated in pancreatic cancer patients, 
although there remains no clinical trial on the effectiveness of this drug as a cancer 
therapeutic. Curcumin has been shown to decrease the levels of  TNF-α ,  NF-κB , 
IL-6, IL-8, IL-10 and COX-2 in colorectal and pancreatic cancer, and multiple 
myeloma (Gupta et al.  2013 ) and may be beneﬁ cial given alongside other chemo-
therapeutics.  Clinical trial s are shortly to start investigating the potential of cur-
cumin to prevent chemotherapy-induced fatigue in breast cancer patients about to 
receive radiotherapy (NCT01740323). 
 One approach that has been taken by scientists at Imperial College London was 
to investigate target genes downstream of  NF-κB in an attempt to avoid some of the 
serious toxic side effects associated with other NF-κB targeted therapies. Tornatore 
and colleagues identiﬁ ed a protein complex, GADD45β/MKK7, that appeared to 
play a critical role in allowing cancer cells to survive. Using high-throughput screen-
ing, the investigators found two molecules that disrupted this protein complex with 
no toxicity to normal cells. This new drug, DTP3, will be entering clinical trials late 
in 2015 for the treatment of multiple myeloma (Tornatore et al.  2014 ). 
10  Conclusion 
 Multiple factors in the tumor microenvironment contribute to the alteration of tumor 
cell function and behavior, including the transition to  CSCs . CSCs represent a very 
ﬂ uid population of cells within the tumor mass that are reactive to environmental 
cues including cytokines secreted from both cancer cells and various tumor associ-
ated cell populations. Collectively, this microenvironment strongly inﬂ uences pro-
gression of the tumor, with the inﬂ ux of immune cells and their involvement in both 
paracrine and autocrine signaling directly contributing to metastatic disease. As a 
result, a new inﬂ ux of therapeutics targeting these cytokine networks are being tri-
aled, with some positive results being achieved. However, understanding of intricate 
details of gene regulation, such as via microRNAs and epigenetic changes, and how 
these impact remain largely unknown. More studies are required to further delineate 
these pathways to elucidate how cytokines that play a role in our immune response 
can be safely targeted to effectively eradicate cancer stem cells. 
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